The art of managing conversions between antiepileptic drugs: Maximizing patient tolerability and quality of life

Pharmaceuticals

Volumn 3, Issue 9, 2010, Pages 2956-2969

  St Louis, Erik K ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiepileptic drugs; Conversion; Epilepsy; Monotherapy; Polytherapy; Quality of life

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE; CARBAMAZEPINE; LAMOTRIGINE; OXCARBAZEPINE; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

AGE; ATAXIA; ATTENTION DISTURBANCE; BIPOLAR DISORDER; BLURRED VISION; CHRONIC DRUG ADMINISTRATION; COARSE FACE; COGNITIVE DEFECT; COMORBIDITY; DIPLOPIA; DISEASE CLASSIFICATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG SAFETY; DRUG SELECTIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAPHY; EPILEPSY; EVIDENCE BASED MEDICINE; FATIGUE; FOCAL EPILEPSY; GENETIC SCREENING; GINGIVA HYPERPLASIA; HEADACHE; HEALTH CARE ACCESS; HIRSUTISM; HUMAN; KIDNEY DISEASE; LIVER DISEASE; LOADING DRUG DOSE; MEMORY DISORDER; MIGRAINE; NEUROIMAGING; PATIENT ATTITUDE; PATIENT CARE; PATIENT COUNSELING; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; TREATMENT PLANNING;

EID: 77957284607     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph3092956     Document Type: Review

References (70)

1. Kwan, P.; Brodie M.J. Epilepsy after the first drug fails: substitution or add-on? Seizure 2000, 9, 464-468.
2. Kwan, P.; Brodie, M.J. Effectiveness of the first antiepileptic drug. Epilepsia 2001, 4, 1255-1260.
3. French, J.A.; Kanner, A.M.; Bautista, J.; Abou-Khalel, B.; Browne, T.; Harden, C.L.; Theodore, W.H.; Bazil, C.; Stern, J.; Schachter, S.C.; Bergen, D.; Hirtz, D.; Montouris, G.D.; Nespecia, M.; Gidal, B.; Marks, Jr., W.J.; Turk, W.R.; Fischer, J.H.; Bourgeois, B.; Wilner, A.; Faught, Jr., R.E.; Sachdeo, R.C.; Beydoun, A.; Glauser, T.A. Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62, 1252-1260.
4. Privitera, M.D., Brodie, M.J., Mattson, R.H.,Chadwick, D.W., Neto, W., Wang, S., EPMN 105 Study Group. Topiramate, carbamazepine, and valproate monotherapy: double-blind comparison in newly diagnosed epilepsy. Acta Neurologica Scandinavia 2003, 107, 165-175.
5. Brodie, M.J.; Richens, A.; Yuen, A.W. Double-blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. UK Lamotrigine-Carbamazepine Monotherapy trial Group. Lancet 1995, 345, 476-479.
6. Rowan, A.J.; Ramsay, R.E.; Collins, J.F.; Pryor, F.; Boardman, K.D.; Uthman, B.M.; Spitz, M.; Frederick, T.; Towne, A.; Carter, G.S.; Marks, W.; Felicetter, J.; Tomyanvich, M.L.; VA Cooperative Study 428 Group. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology 2005, 64, 1868-1873.
7. Gilliam, F.; Hecimovic, H.; Sheline, Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 2003, 4 (Suppl. 4), S26-S30.
8. Gilliam, F.G.; Mendiratta, A.; Pack, A.M.; Bazil, C.W. Epilepsy and common comorbidities: improving the outpatient epilepsy encounter. Epileptic Disord 2005, 7 (Suppl. 1), S27-S33.
9. Naritoku, D.K.; Hulihan, J.F.; Schwarzman, L.K.; Kamin, M.; Olson, W.H. Effect of cotherapy reduction on tolerability of epilepsy add-on therapy: a randomized controlled trial. Annals of Pharmacotherapy 2005, 39, 418-423.
10. Leone, M.A.; Beghi, E.; Righini, C.; Apolone, G.; Mosconi, P. Epilepsy and quality of life in adults: a review of instruments. Epilepsy Res. 2005, 66, 23-44.
11. Privitera, M.; Ficker, D. Assessments of adverse events and quality of life in epilepsy: design of a new community trial. Epilepsy Behav. 2004, 5, 841-846.
12. Baker, G.A.; Jacoby, A.; Buck, D.; Stalgis, C.; Monnett, D. Quality of life of people with epilepsy: a European study. Epilepsia 1997, 38, 353-362.
13. Mattson, R.M.; Cramer, J.A.; Collins, J.F.; Smith, D.B.; Delgado-Esceuta, A.V.; Browne, T.R.; Williamson, P.D.; Trelman, D.M.; McNamara, J.O.; McCutchen, C.D. Comparison of phenobarbital, phenytoin, carbamazepine, and primidone in partial and secondary generalized tonic-clonic seizures. New Engl. J. Med. 1985, 313, 145-151.
14. Baker, G.A.; Camfield, C.; Camfield, P.; Crammer, J.A.; Elger, C.E.; Johnson, A.L.; Martins da Silva, A.; Mindardi, H.; Munari, C.; Perucca, E.; Thorbecke, R. Commission on Outcome Measurement in Epilepsy, 1994-1997: Final report. Epilepsia 1998, 39, 213-231.
15. Gilliam, F.G.; Fessler, A.J.; Baker, G.; Vahle, V.; Carter, J.; Ararian, H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 2004, 62, 23-27.
16. St. Louis, E.K. Minimizing AED adverse effects: improving quality of life in the interictal state in epilepsy care. Curr. Neuropharmacol. 2009, 7, 106-114.
17. Baulac, M. Rational conversion from antiepileptic polytherapy to monotherapy. Epileptic Disorders 2003, 5, 125-132.
18. St. Louis, E.K. Truly rational polytherapy: maximizing efficacy and minimizing drug interactions, drug load, and adverse effects. Curr. Neuropharmacol. 2009, 7, 96-105.
19. St. Louis, E.K.; Rosenfeld, W.E.; Bramley, T. Antiepileptic drug monotherapy: the initial approach in epilepsy management. Curr. Neuropharmacol. 2009, 7, 77-82.
20. French, J.A.; Kanner, A.M.; Bautista, J.; Abou-Khalel, B.; Browne, T.; Harden, C.L.; Theodore, W.H.; Bazil, C.; Stern, J.; Schachter, S.C.; Bergen, D.; Hirtz, D.; Montouris, G.D.; Nespecia, M.; Gidal, B.; Marks, Jr., W.J.; Turk, W.R.; Fischer, J.H.; Bourgeois, B.; Wilner, A.; Faught, Jr., R.E.; Sachdeo, R.C.; Beydoun, A.; Glauser, T.A. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology; Quality Standards Subcommittee of the American Academy of Neurology; American Epilepsy Society. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004, 62, 1261-1273.
21. Reife, R.; Pledger, G.; Wu, S.C. Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults. Epilepsia 2000, 41 (Suppl. 1), S66-S71.
22. Brodie, M.J.; Yuen, A.W. Lamotrigine substitution study: evidence for synergism with sodium valproate? 105 Study Group. Epilepsy Res. 1997, 26, 423-432.
23. Carpay, J.A.; Aldenkamp, A.P.; van Donselaar, C.A. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 2005, 14, 198-206.
24. Kwan, P.; Brodie, M.J. Early identification of refractory epilepsy. NEJM 2000, 342, 314-319.
25. Cramer, J. Exploration of changes in health-related quality of life after 3 months of vagus nerve stimulation. Epilepsy Behav. 2001, 2, 460-465.
26. Engel, Jr., J.; Weibe, S.; French, J.; Sperling, M.; Williamson, P.; Spencer, D.; Gumnit, R.; Zahn, C.; Westbrook, E.; Enos, B. Practice parameter: temporal lobe and localized neocortical resections for epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology, in association with the American Epilepsy Society and the American Association of Neurological Surgeons. Neurology 2003, 60, 538-547.
27. Morris, G.L., 3rd; Mueller, W.M. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology 1999, 53, 1731-1735.
28. Renfroe, J.B.; Wheless, J.W. Earlier use of adjunctive vagus nerve stimulation therapy for refractory epilepsy. Neurology 2002, 59, 6 (Suppl. 4), S26-S30.
29. Tellez-Zenteno, J.F.; Dhar, R.; Wiebe, S. Long-term seizure outcomes following epilepsy surgery: a systematic review and meta-analysis. Brain 2005, 128, 1188-1198.
30. Wiebe, S.; Blume, W.T.; Girvin, J.P.; Eliasziw, M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. New Engl. J. Med. 2001, 345, 311-318.
31. Labar, D.R. Antiepileptic drug use during the first 12 months of vagus nerve stimulation therapy: a registry study. Neurology 2002, 59, S38-S43.
32. St. Louis, E.K.; Chang, S.; Granner, M.A.; Howard, M.; Kawasaki, H. Reduction of antiepileptic drug treatment following epilepsy surgery. Epilepsia 2007, 48, 150.
33. Malow, B.A.; Bowes, R.J.; Lin, X. Predictors of sleepiness in epilepsy patients. Sleep 1997, 20, 1105-1110.
34. Malow, B.A.; Levy, K.; Maturen, K.; Bowes, R. Obstructive sleep apnea is common in medically refractory epilepsy patients. Neurology 2000, 55, 1002-1007.
35. Malow, B.A.; Weatherwax, K.J.; Chervin, R.D.; Hoban, T.F.; Marzec, M.C.; Martin, C.; Binns, L.A. Identification and treatment of obstructive sleep apnea in adults and children with epilepsy: a prospective pilot study. Sleep Med. 2003, 4, 509-515.
36. St. Louis, E.K. To sleep, perchance to seize: the odd marriage of sleep and epilepsy. Am. J. Electroneurodiagn. Tech. 2003, 43, 130-163.
37. Karceski, S.; Morrell, M.J.; Carpenter, D. Treatment of epilepsy in adults: expert opinion. 2005, Epilepsy Behav. 2005, 7, S1-S64.
38. Messenheimer, J.; Mullens, E.; Giorgi, L.; Young, F. Safety review of adult clinical trial experience with lamotrigine. Drug Safety 1998, 18, 281-296.
39. St. Louis, E.K.; Gidal, B.E.; Henry, T.R.; Kaydanova, Y.; Krumholz, A.; McCabe, P.H.; Montouris, G.D.; Rosenfeld, W.E.; Smith, B.J.; Stern, J.M.; Waterhouse, E.J.; Schulz, R.M.; Garnett, W.R.; Bramley, T. Conversions between monotherapies in epilepsy: expert consensus. Epilepsy Behav. 2007, 11, 222-234.
40. Harms, S.L; Eberly, L.E.; Garrard, J.M.; Hardie, N.A.; Bland, P.C.; Leppik, I.E. Prevalence of appropriate and problematic antiepileptic combination therapy in older people in the nursing home. JAGS 2005, 53, 1023-1028.
41. Mamiya, K.;Yukawa, E.; Matsumoto, T.; Aita, C.; Goto, S. Synergistic effect of valproate coadministration and hypoalbuminemia on the serum-free phenytoin concentration in patients with severe motor and intellectual disabilities. Clin. Neuropharmacol. 2002, 25, 230-233.
42. Johannessen Landmark, C.; Patsalos, P.N. Drug interactions involving the new second- and thirdgeneration antiepileptic drugs. Expert Rev. Neurother. 2010, 10, 119-140.
43. Pack, A.M.; Morrell, M.J. Epilepsy and bone health in adults. Epilepsy Behav. 2004, 5, S24-S29.
44. Souverein, P.C.; Webb, D.J.; Weil, J.G.; Weil, J.G.; Van Staa, T.P.; Egberts, A.C.G. Use of antiepileptic drugs and risk of fractures: case-control study among patients with epilepsy. Neurology 2006, 66, 1318-1324.
45. Sheth, R.D. Metabolic concerns associated with antiepileptic medications. Neurology 2004, 63, S24-S29.
46. Bell, G.S.; Mula, M.; Sander, J.W. Suicidality in people taking antiepileptic drugs: What is the evidence? CNS Drugs 2009, 23, 281-292.
47. Hesdorffer, D.C.; Kanner, A.M. The FDA alert on suicidality and antiepileptic drugs: Fire or false alarm? Epilepsia 2009, 50, 978-986.
48. Mintzer, S. Metabolic consequences of antiepileptic drugs. Curr. Opin. Neurol. 2010, 23, 164-169.
49. Mintzer, S.; Skidmore, C.T.; Abidin, C.J.; Morales, M.C.; Chervoneva, I.; Capuzzi, D.M.; Sperling, M.R. Effects of antiepileptic drugs on lipids, homocysteine, and C-reactive protein. Ann. Neurol. 2009, 65, 448-456.
50. Hung, S.I.; Chung, W.H.; Jee, S.H.; Chen, W.C.; Chang, Y.T.; Lee, W.R.; Hu, S.L.; Wu, M.T.; Chen, G.S.; Wong, T.W.; Hsiao, P.F.; Chen, W.H.; Shih, H.Y.; Fang, W.H.; Wei, C.Y.; Lou, Y.H.; Huang, Y.L.; Lin, J.J.; Chen, Y.T. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. Pharmacogenet. Genomics 2006, 16, 297-306.
51. Man, C.B.; Kwan, P.; Baum, L.; Yu, E.; Lau, K.M.; Cheng, A.S.; Ng, M.H. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007, 48, 1015-1018.
52. St.Louis, E.K. Monitoring antiepileptic drugs: a level-headed approach. Curr. Neuropharmacol. 2009, 7, 115-119.
53. Garnett, W.R.; St Louis. E.K.; Henry, T.R.; Bramley, T. Transitional polytherapy: tricks of the trade for monotherapy to monotherapy AED conversions. Curr. Neuropharmacol. 2009, 7, 83-95.
54. Fisher, R.S.; Sachdeo, R.C.; Pellock, J.; Penovich, P.E.; Magnus, L.; Bernstein, P. Rapid initiation of gabapentin: a randomized, controlled trial. Neurology 2001, 56, 743-748.
55. French, J.; Arrigo, C. Rapid onset of action of levetiracetam in refractory epilepsy patients. Epilepsia 2005, 46, 324-326.
56. Mauro, A.M.; Bomprezzi, C.; Morresi, S.; Provinciali, L.; Formica, F.; Iacoangeli, M.; Scerrati, M. Prevention of early postoperative seizures in patients with primary brain tumors: preliminary experience with oxcarbazepine. J. Neurooncol. 2007, 81, 279-285.
57. Pledger, G. Monotherapy trials: presurgical studies. Epilepsy Res. 2001, 45, 67-71, discussion 73-74.
58. Towne, A.R.; Garnett, L.K.; Waterhouse, E.J.; Morton, L.D.; DeLorenzo, R.J. The use of topiramate in refractory status epilepticus. Neurology 2003, 60, 332-334.
59. Biton, V.; Rosenfeld, W.E.; Whitesides, J.; Fountain, N.B.; Vaiciene, N.; Rudd, G.D. Intravenous lacosamide as replacement for oral lacosamide in patients with partial-onset seizures. Epilepsia 2008, 49, 418-424.
60. Gilad, R.; Izkovitz, N.; Dabby, R.; Rapoport, A.; Sadeh, M.; Weller, B.; Lampl, Y. Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs. phenytoin. Acta Neurol Scand. 2008, 118, 296-300.
61. Szaflarski, J.P.; Sangha, K.S.; Lindsell, C.J.; Shutter, L.A. Prospective, randomized, singleblinded comparative trial of intravenous levetiracetam versus phenytoin for seizure prophylaxis. Neurocrit Care 2010, 12, 165-172.
62. Bohan, K.H.; Mansuri, T.F.; Wilson, N.M. Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 2007, 27, 1425-1439.
63. Kwan, P.; Arzimanoglou, A.; Berg, A.T.; Brodie, M.J.; Allen, H.W.; Mathern, G.; Moshé, S.L.; Perucca, E.; Wiebe, S.; French, J. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010, 51, 1069-1077.
64. Patsalos, P.N.; Froscher, W.; Pisani,.F; van Rijn, C.M. The importance of drug interactions in epilepsy therapy. Epilepsia 2002, 43, 365-385.
65. Anderson, G.D.; Gidal, B.E.; Messenheimer, J.A.; Gilliam, F.G. Time course of lamotrigine deinduction: impact of step-wise withdrawal of carbamazepine or phenytoin. Epilepsy Res. 2002, 49, 211-217.
66. Meador, K.J. Cognitive outcomes and predictive factors in epilepsy. Neurology 2002, 58, S21-S26.
67. Rahmann, A.; Stodieck, S.; Husstedt, I.W.; Evers, S. Pre-attentive cognitive processing in epilepsy: a pilot study on the impact of epilepsy type and anti-epileptic treatment. European Neurology 2002, 48, 146-152.
68. rd International Driving Symposium on Human Factors in Driver Assessment, Training, and Vehicle Design, University of Iowa Press: Iowa City, Iowa, 2005.
69. St Louis, E.K.; Dennhardt, J.; Luck, S.J. Visual attention is impaired in epilepsy. Epilepsia 2006, 47, 104.
70. Smith, B.J.; St Louis, E.K.; Stern, J.M.; Green, C.; Bramley, T. Concerns with AED conversion: comparison of patient and physician perspectives. Curr. Neuropharmacol. 2009, 7, 120-124.